



ShareSoc

UK Individual Shareholders Society

PO Box 62, Chislehurst, BR7 5YB

Phone: 0333-200-1595

Email: info@sharesoc.org

Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to the ShareSoc Members Network (<http://sharesoc.ning.com>) in a Forum entitled "ShareSoc Growth Company Seminar Reports" soon after the Seminar. Use the site search facility at top right to locate those for a particular company if you cannot find the Forum.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Ergomed

ERGO  122.5p  0.0 0.0%

Market Cap	£48.8m	Value	37
Enterprise Value	£44.9m	Quality	68
Revenue	£30.2m	Momentum	22
Position in Universe	1047th / 1794	StockRank™	34



Momentum	
Relative Strength (%)	
1m	-15.8%
3m	-23.0%
1yr	-31.2%
Volume Change (%)	
10d v 3m	-45.7%
Price vs... (%)	
52w High	-34.5%
50d MA	-7.61%
200d MA	-21.4%



Growth & Value	
12m Forecast Rolling	
PE Ratio (f)	41.5
PEG Ratio (f)	n/a
EPS Growth (f)	-39.7 %
Dividend Yield (f)	n/a %
Valuation (ttm)	
Price to Book Value	2.88
Price to Tang. Book	7.37
Price to Free Cashflow	n/a
Price to Sales	1.62
EV to EBITDA	16.1

Margin of Safety (beta)	
Broker Target	115%
Relative to Sector	6%
Graham Formula	30%
Stability Value (EPV)	63%

Screens Passed 1 / 1	
	ERGO qualifies for Neglected Firms Screen (in Value Investing).

Quality	
Return on Capital	11.9 %
Return on Equity	9.62 %
Operating Margin	6.87 %

Financial Summary		Balance Sheet · Income Statement · Cashflow								
Year End 31st Dec		2010	2011	2012	2013	2014	2015	2016E	2017E	CAGR / Avg
Revenue	£m	0.000	12.1	14.6	15.1	21.2	30.2	33.7	37.5	+25.8%
Operating Profit	£m	0.000	0.62	0.47	1.78	0.78	2.07			+35.2%
Net Profit	£m	0.000	0.54	0.40	1.55	0.58	1.55	1.40	0.80	+30.5%
EPS Reported	p	0.000	1.86	1.36	7.38	2.31	5.21			+29.4%
EPS Normalised	p	0.000	1.86	1.36	7.38	4.04	5.99	4.00	2.10	+34.0%
EPS Growth	%			-26.9	+442.9	-45.3	+48.4	-33.2	-47.5	
PE Ratio	x					20.4	30.6	58.3		
PEG	x					n/a	n/a	0.078		
Profitability										
Operating Margin	%		5.1	3.2	11.7	3.7	6.9			+6.1%
ROA	%		23.5	8.9	28.3	4.1	6.7			
ROCE	%		82.4	121.1	92.7	4.9	11.9			+62.6%
ROE	%		143.2	71.1	136.8	6.7	9.6			+73.5%
Cashflow										
Op. Cashflow ps	p	0.000	-1.26	2.02	6.58	2.14	0.89			
Capex ps	p	0.000	0.17	0.34	0.34	0.59	1.86			+83.8%
Free Cashflow ps	p	0.000	-1.42	1.69	6.25	1.56	-0.98			
Dividends										
Dividend ps	p									
Dividend Growth	%									
Dividend Yield	%									
Dividend Cover	x									
Balance Sheet										
Cash etc	£m	0.000	0.65	0.45	1.95	4.58	3.97			+57.7%
Working Capital	£m	n/a	0.58	0.21	0.44	5.16	6.27			+81.4%
Net Fixed Assets	£m	0.000	0.18	0.19	0.15	0.55	0.89			+50.3%
Net Debt	£m	0.000	-0.64	-0.35	-1.91	-4.56	-3.96			
Book Value	£m	0.000	0.75	0.36	1.91	15.3	16.9			+118.2%
Average Shares	m	0.000	28.8	28.8	20.9	25.1	29.8			+0.9%
Book Value ps	p	0.000	2.60	1.23	6.63	53.4	58.9			+118.2%




Earnings Manipulation Risk High

Magic Formula Score 943 67% B-


Other Ratios	
Leverage (ttm)	total ex intang
Gross Gearing	% 0.071 0.19
Net Gearing	% -23.4 -59.8
Cash / Assets	% 16.1
Liquidity (ttm)	Efficiency (ttm)
Curr. Ratio	1.87
Quick Ratio	1.87
Interest Cov.	n/a
Asset Turnover	1.28
Rec's Turnover	3.77
Stock Turnover	n/a

Recent History	
Latest interim period (ended 31st Dec '15) vs. prior year	
Sales Growth	17.9 %
EPS Growth	289.1 %
3yr Compound Annual Growth Rate	
Sales Growth	27.4 %
EPS Growth	63.9 %
DPS Growth	n/a %


Graphical History Current Fiscal Year 2016



Broker Forecasts	31st Dec 2016	31st Dec 2017
------------------	---------------	---------------



Price Target: 2.63 (+114.71% above Price)	Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a	(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate	1.40m	4.00	-	800k	2.10	-
1m Change	-	-	-	-	-	-
3m Change	-1,000k	-6.40	-0.60	-2,000m	-9.65	-0.65



Profile Summary



Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company's therapeutic focus is on oncology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs. The Company operates in two segments: The services business and the co-development business. The clinical development services offered by the Company include study management, site management, study physician support, safety services, regulatory and quality management, clinical data management and biostatistics, and medical writing. It has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies. The Company also has co-development deals with other companies.

Directors: Miroslav Reljanovic (CEO), Stephen Stamp (CFO) 54, Neil Clark (CEX) 53, Andrew Mackie (EDR) 50, Danko Dominis (OTH), Branka Duvnjak (OTH), Terry Murdock (OTH) 49, Chris Wilson (OTH), Rolf Stahel (NEC) 71, Peter George (NED),

No. of Employees: 150

No. of Shareholders: n/a

Last Annual	December 31st, 2015
Last Interim	December 31st, 2015
Incorporated	September 29, 2000
Public Since	July 15, 2014
Shares in Issue	39,864,230
Free Float	20.5m (51.4%)

Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? ☒ a SIPP? ☒




Address 26-24 Frederick Sanger Road,
GUILDFORD, GU2 7YD, United Kingdom
Web <http://ergomedgroup.com/>
Phone +44 1483 503205
Contact ()
Auditors Deloitte LLP

ERGOQuote

ERGO Share Price **Day's Change**
 GBP
122.5p **0.0 0.0%**
 Traded 12:46pm · Minimum 15 min delayed · NMS: 1.50k

Volume 36,081	Bid - Ask 121.0 - 124.0	Low - High 0.0 - 0.0	Spread 245bps
Avg Vol (3m) 8,910	Open - Close 122.5 - 122.5	12m Range 135.0 - 171.0	Beta 0.00

ERGO Share Price Performance



Latest ERGO News Announcements (delayed)

[More »](#)

27th Jun	Result of AGM
27th Jun	US expansion and opening of office in Bo...
20th Jun	Notice of AGM
14th Jun	Holding(s) in Company
13th Jun	Acquisition

Upcoming ERGO Events

Recent ↓

Industry Peer Group

	Mainstay Medical I... Compare vs ERGO
	Silence Therapeuti... Compare vs ERGO
	ReNeuron Compare vs ERGO
	Oxford BioMedica Compare vs ERGO
	Horizon Discovery Compare vs ERGO
	Tissue Regenix Compare vs ERGO
	Verseon Compare vs ERGO
	Vernalis Compare vs ERGO

[Healthcare](#) [Biotechnology & Medical Research](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Ideagen

IDEA 55.25p ▲ 0.3 0.5%

Market Cap	£99.0m	Value	4
Enterprise Value	£93.6m	Quality	69
Revenue	£18.6m	Momentum	81
Position in Universe	875th / 1794	StockRank™	48



Momentum	
Relative Strength (%)	
1m	-4.2%
3m	+4.2%
1yr	+22.5%
Volume Change (%)	
10d v 3m	-54.3%
Price vs... (%)	
52w High	-7.9%
50d MA	+2.74%
200d MA	+9.17%



Growth & Value	
12m Forecast Rolling	
PE Ratio (f)	18.0
PEG Ratio (f)	1.45
EPS Growth (f)	14.1 %
Dividend Yield (f)	0.37 %
Valuation (ttm)	
Price to Book Value	3.11
Price to Tang. Book	n/a
Price to Free Cashflow	127.7
Price to Sales	5.32
EV to EBITDA	23.3

Margin of Safety (beta)	
Broker Target	-44%
Relative to Sector	10%
Graham Formula	-31%
Stability Value (EPV)	+73%

Screens Passed	
IDEA doesn't qualify for any screens.	
Find out why: View Checklists	

Quality	
Return on Capital	0.59 %
Return on Equity	0.48 %
Operating Margin	1.19 %

Financial Summary								Balance Sheet • Income Statement • Cashflow				
Year End 30th Apr		2010	2011	2012	2013	2014	2015	TTM	2016E	2017E	CAGR / Avg	
Revenue	£m	0.97	2.25	4.00	6.51	8.97	14.4	18.6	21.8	23.9	+71.6%	
Operating Profit	£m	0.066	0.27	0.29	-1.45	1.06	0.80	0.23			+64.4%	
Net Profit	£m	0.073	0.57	0.11	-0.81	0.88	0.48	0.11			+46.1%	
EPS Reported	p	0.21	1.03	0.15	-0.88	0.69	0.34	0.068			+9.9%	
EPS Normalised	p	0.25	1.30	0.73	0.65	0.84	0.59	0.23	2.69	3.07	+19.0%	
EPS Growth	%		+431.8	-44.6	-10.1	+29.1	-30.3	-61.3	+360.6	+14.1		
PE Ratio	x						94.6	244.5	20.5	18.0		
PEG	x						0.27	0.68	1.45	n/a		
Profitability												
Operating Margin	%	6.8	11.7	7.1	-22.3	11.8	5.5	1.19			+3.4%	
ROA	%		15.8	1.4	-6.0	4.8	1.4	0.23				
ROCE	%	5.7	8.6	4.0	-11.1	7.2	2.1	0.59			+2.8%	
ROE	%		29.0	2.5	-8.9	6.8	2.2	0.48			+6.3%	
Cashflow												
Op. Cashflow ps	p	-0.72	-0.076	1.39	1.76	0.96	1.23	1.53				
Capex ps	p	0.008	0.29	0.22	0.52	0.46	0.73	1.04			+150.8%	
Free Cashflow ps	p	-0.73	-0.36	1.17	1.25	0.50	0.51	0.50				
Dividends							Last ex-div: 18th Feb, paid: 10th Mar more...					
Dividend ps	p					0.15	0.17	0.18	0.19	0.20		
Dividend Growth	%						+10.00	+3.64	+10.3	+9.89		
Dividend Yield	%						0.30	0.31	0.33	0.37		
Dividend Cover	x					4.54	2.04	0.40	14.8	15.4		
Balance Sheet												
Cash etc	£m	0.23	0.77	1.50	6.37	4.01	5.27	5.44			+88.7%	
Working Capital	£m	-0.17	-0.33	-0.80	4.95	2.60	1.23	2.69				
Net Fixed Assets	£m	0.059	0.29	0.32	0.41	0.34	1.18	1.30			+82.0%	
Net Debt	£m	-0.19	-0.76	-1.39	-6.37	-4.01	-5.27	-5.44				
Book Value	£m	0.86	3.07	5.79	12.3	13.4	31.2	31.8			+105.1%	
Average Shares	m	34.4	55.5	75.9	92.1	128.3	143.1	157.8			+33.0%	
Book Value ps	p	1.69	4.40	7.43	10.1	11.0	17.6	17.9			+59.8%	




Earnings Manipulation Risk: Low

Magic Formula Score: 1457 47% C-


Other Ratios		
Leverage (ttm)	total	ex intang
Gross Gearing	%	0.000
Net Gearing	%	-17.1
Cash / Assets	%	11.3
Liquidity (ttm)		Efficiency (ttm)
Curr. Ratio	1.27	Asset Turnover
Quick Ratio	1.26	Rec's Turnover
Interest Cov.	100.0	Stock Turnover
		39.1

Recent History		
Latest interim period (ended 31st Oct '15) vs. prior year		
Sales Growth	74.5 %	
EPS Growth	-99.1 %	
3yr Compound Annual Growth Rate		
Sales Growth	53.2 %	
EPS Growth	-6.83 %	
DPS Growth	n/a %	



Broker Forecasts	30th Apr 2016	30th Apr 2017	Broker Consensus Trend
			1 Brokers

Price Target: 0.61 (+10.41% above Price)	Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a	(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate	-	2.69	0.19	-	3.07	0.20
1m Change	-	-	-	-	-	-
3m Change	-	-	-	-	-	-



Profile Summary

ideagen Ideagen plc is a provider of enterprise governance, risk, and compliance (eGRC) and healthcare information management software for organizations operating within regulated industries. The Company offers GRC solutions, which offers products, such as Pentana, Q-Pulse, Quality Workbench, Proquis Enterprise, KnowledgeWorker and Ideagen Capture. It offers GRC solutions for industries, such as accounting and finance, aerospace and defense, automotive, and others. The Company offers healthcare solutions, which offers products, such as dartCAPTURE, dartED, dartEMR, dartKW, dartOCM, dartQSCAN, PatientFirst and Q-Pulse. It offers healthcare solutions for departments, such as medical record archiving, pathology (laboratory), radiology and others. The Company offers content solution, such as Easysite, which manages sites online, inline and in real time. It offers Easysite for content management, digital asset management, site management, social and personalization, Context Management and others.



Directors: David Hornsby (CEO), Graeme Spenceley (FID), Jonathan Wearing (NEC), Alan Carroll (NED),

No. of Employees: 163

No. of Shareholders: n/a

Last Annual	April 30th, 2015	Sector	Technology
Last Interim	October 31st, 2015	Industry	Software & IT Services
Incorporated	March 30, 1993	Index	FTSE Aim All Share ,
Shares in Issue	179,184,428	Exchange	London Stock Exchange (AIM)
Free Float	157.7m (88.0%)	Eligible for	an ISA? ☒ a SIPP? ☒


Address Lime Tree Business Park Lime Tree Road, MATLOCK, DE4 3EJ, United Kingdom
Web <http://www.ideagenplc.com/>
Phone +44 1629 699100
Contact Paul Cornelius (IR Contact Officer)
Auditors Baker Tilly UK Audit LLP

IDEAQuote

IDEA Share Price **Day's Change**
GBp
55.25p **▲ 0.3 0.5%**
Traded 4:24pm · Minimum 15 min delayed · NMS: 7.50k

Volume	Bid - Ask	Low - High	Spread
148,007	54.5 - 56.0	0.0 - 0.0	271bps
Avg Vol (3m)	Open - Close	12m Range	Beta
197,921	55.0 - 55.3	48.0 - 55.0	0.11

IDEA Share Price Performance



Latest IDEA News Announcements (delayed)

12th Jul	Notice of Results
5th Jul	Holding(s) in Company
29th Jun	Holding(s) in Company
18th May	Pre-Close Trading Update
5th May	Exercise of Options and Total Voting Rig...

Upcoming IDEA Events

Tuesday 19th July, 2016
Full Year 2016 Ideagen PLC Earnings Release

Recent ↓

Industry Peer Group

	Blue Prism Compare vs IDEA
	Actual Experience Compare vs IDEA
	IMImobile Compare vs IDEA
	K3 Business Techno... Compare vs IDEA
	dotDigital Compare vs IDEA
	Keywords Studios Compare vs IDEA
	Idox Compare vs IDEA
	accesso Technology Compare vs IDEA

[Technology](#)

[Software & IT Services](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

IMImobile

IMO  173.5p  0.0 0.0%

Market Cap	£105.1m	Value	 29
Enterprise Value	£98.5m	Quality	 90
Revenue	£61.6m	Momentum	 98
Position in Universe	854th / 1790	StockRank™	 88

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All




Momentum

Relative Strength (%)	
1m	+0.5%
3m	+10.8%
1yr	+12.1%
Volume Change (%)	
10d v 3m	-55.1%
Price vs... (%)	
52w High	-0.9%
50d MA	+7.51%
200d MA	+13.5%

Growth & Value

12m Forecast Rolling		vs. industry	vs. market
PE Ratio (f)	15.0		
PEG Ratio (f)	0.41		
EPS Growth (f)	58.0 %		
Dividend Yield (f)	n/a %		
Valuation (ttm)			
Price to Book Value	2.99		
Price to Tang. Book	9.51		
Price to Free Cashflow	20.1		
Price to Sales	1.71		
EV to EBITDA	14.5		

Margin of Safety (beta)



Screens Passed 2


IMO qualifies for **52 Week High Momentum Screen (in Momentum Investing)**.

Financial Summary

Balance Sheet • Income Statement • Cashflow

Year End 31st Mar		2011	2012	2013	2014	2015	2016	2017E	2018E	CAGR / Avg
Revenue	£m	30.3	38.7	38.5	43.4	48.9	61.6	70.5	76.9	+15.3%
Operating Profit	£m	-2.65	3.14	2.96	5.24	-2.30	4.08			
Net Profit	£m	-3.73	1.84	2.10	3.92	-5.98	3.41	7.40	8.10	
EPS Reported	p	-7.88	3.89	4.45	8.29	-13.5	5.21			
EPS Normalised	p	0.018	4.11	4.51	7.86	-11.0	5.67	11.3	12.2	+216%
EPS Growth	%		+22,728	+9.8	+74.2			+99.4	+7.96	
PE Ratio	x						30.6	15.4	14.2	
PEG	x						0.31	1.93	1.74	
Profitability										
Operating Margin	%	-8.8	8.1	7.7	12.1	-4.7	6.6			+3.5%
ROA	%		4.7	5.3	9.2	-11.4	5.3			
ROCE	%	-12.9	14.7	12.7	20.9	-5.8	9.2			+6.5%
ROE	%		39.8	25.4	32.8	-27.6	10.6			+16.2%
Cashflow										
Op. Cashflow ps	p	13.6	4.42	13.9	18.5	18.6	13.4			-0.3%
Capex ps	p	7.95	4.95	3.27	3.95	3.70	5.41			-7.4%
Free Cashflow ps	p	5.64	-0.54	10.6	14.5	14.9	7.99			+7.2%
Dividends										
Dividend ps	p									
Dividend Growth	%									
Dividend Yield	%									
Dividend Cover	x									
Balance Sheet										
Cash etc	£m	1.88	2.02	4.64	9.27	14.6	15.0			+51.6%
Working Capital	£m	2.93	3.70	6.59	10.3	14.3	14.9			+38.4%
Net Fixed Assets	£m	9.51	9.43	8.29	6.43	5.48	5.36			-10.8%
Net Debt	£m	18.1	14.6	9.71	1.63	-14.6	-15.0			
Book Value	£m	2.67	6.58	10.00	13.9	29.4	35.2			+67.4%
Average Shares	m	47.3	47.3	47.3	47.3	44.3	65.4			+6.7%
Book Value ps	p	5.65	13.9	21.1	29.4	61.3	71.5			+66.1%

Health Trend



Bankruptcy Risk



Earnings Manipulation Risk

Low

Magic Formula Score

968 65% B-


Other Ratios

Leverage (ttm)		total	ex intang
Gross Gearing	%	0.000	0.000
Net Gearing	%	-42.8	-136.1
Cash / Assets	%	21.8	
Liquidity (ttm)			
Curr. Ratio	1.61	Asset Turnover	0.93
Quick Ratio	1.61	Rec's Turnover	2.96
Interest Cov.	100.0	Stock Turnover	n/a

Recent History

Latest interim period (ended 31st Mar '16) vs. prior year		vs. industry	vs. market
Sales Growth	23.6 %		
EPS Growth	176 %		
3yr Compound Annual Growth Rate			
Sales Growth	17.0 %		
EPS Growth	7.92 %		
DPS Growth	n/a %		

Graphical History Current Fiscal Year 2017



Broker Forecasts


31st Mar 2017

31st Mar 2018

Broker Consensus Trend

1 Brokers

Price Target: 2.10 (+21.01% above Price)						
Est. Long Term Growth Rate: n/a	(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate	7.40m	11.3	-	8.10m	12.2	-
1m Change	+200k	+0.70	-	+300k	+0.70	-
3m Change	+200k	+0.70	-	+300k	+0.70	-



Profile Summary



IMImobile PLC is a United Kingdom-based technology company, which provides software and services. The Company's segments include Europe (substantially all to the United Kingdom), India and South East Asia (SEA), Middle East and Africa (MEA) and the rest of the world. Its delivery models include managed solutions, software as a service (SaaS) and license fees. Its DaVinci Evolved Service Platform provides an environment to create, deliver and manage a range of cross-channel enterprise and consumer services. Its DaVinci Content Management System supports the delivery of an array of content types to the universe of connected devices from basic feature phones and personal computers (PCs) to smartphones, tablets and in-car infotainment systems. Its DaVinci Social aggregates high volumes of inbound customer audience messages from multiple channels. Its Campaign Manager enables omnichannel marketing campaigns. Its TextLocal is a SaaS business messaging tool.

Directors: Jayesh Patel (CEO) 44, Shyamprasad Subramanya (FDR) 54, Michael Jefferies (SEC) 36, John Allwood (NEC) 64, Viswanatha Reddy Alluri (NED) 61, Simon Blagden (NID) 52,

No. of Employees: 750

No. of Shareholders: n/a

Last Annual	March 31st, 2016
Last Interim	March 31st, 2016
Incorporated	December 4, 2013
Public Since	June 27, 2014
Shares in Issue	60,599,282
Free Float	56.6m (93.4%)

Sector Technology
Industry Software & IT Services
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? ☒ a SIPP? ☒




Address 1 Cliveden Office Village, Lancaster Road, HIGH WYCOMBE, HP12 3YZ, United Kingdom
Web <http://www.imimobile.com/>
Phone +44 1494 750500
Contact ()
Auditors Deloitte LLP

IMOQuote

IMO Share Price **Day's Change**
 GBP **173.5p**
 Traded 3:53pm · Minimum 15 min delayed · NMS: 3.00k

Volume	Bid - Ask	Low - High	Spread
34,042	173.0 - 174.0	0.0 - 0.0	58bps
Avg Vol (3m)	Open - Close	12m Range	Beta
71,347	173.5 - 173.5	150.0 - 173.0	0.00

IMO Share Price Performance



Latest IMO News Announcements (delayed)

[More »](#)

6th Jul	Exercise of Options
5th Jul	Preliminary Results
23rd Jun	Holding(s) in Company
23rd Jun	Holding(s) in Company
16th May	Holding(s) in Company

Upcoming IMO Events

Wednesday 7th September, 2016 (Estimate)
 IMImobile PLC Annual Shareholders Meeting

[Recent ↓](#)

Industry Peer Group

	Blue Prism Compare vs IMO
	Ideagen Compare vs IMO
	Actual Experience Compare vs IMO
	K3 Business Techno... Compare vs IMO
	dotDigital Compare vs IMO
	Keywords Studios Compare vs IMO
	Idox Compare vs IMO
	accesso Technology Compare vs IMO

[Technology](#)

[Software & IT Services](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.

Palace Capital

PCA  317.5p  0.0 0.0%

Market Cap	£81.4m	Value	84
Enterprise Value	£146.9m	Quality	52
Revenue	£14.6m	Momentum	 83
Position in Universe	911th / 1794	StockRank™	



Momentum

Relative Strength (%)	
1m	-17.2% 
3m	-10.6% 
1yr	-10.8% 
Volume Change (%)	
10d v 3m	-2.78% 
Price vs... (%)	
52w High	-19.1% 
50d MA	-8.05% 
200d MA	-9.17% 

Growth & Value

12m Forecast Rolling		vs. industry	vs. market
PE Ratio (f)	14.3		
PEG Ratio (f)	n/a		
EPS Growth (f)	-43.6 %		
Dividend Yield (f)	5.23 %		
Valuation (ttm)			
Price to Book Value	0.77		
Price to Tang. Book	0.77		
Price to Free Cashflow	8.91		
Price to Sales	5.58		
EV to EBITDA	14.5		

Margin of Safety (beta)

Relative to Sector	6%
Graham Formula	89%
Stability Value (EPV)	490%

Screens Passed

PCA doesn't qualify for any screens.
Find out why: [View Checklists](#)

Quality

Return on Capital	7.85 %		
Return on Equity	11.6 %		
Operating Margin	96.0 %		

Financial Summary

Balance Sheet • Income Statement • Cashflow

Year End 31st Mar		2011	2012	2013	2014	2015	2016	2017E	2018E	CAGR / Avg
Revenue	£m	0.000	0.056	0.20	0.22	8.64	14.6	12.8	13.7	
Operating Profit	£m	-0.077	0.059	-0.032	21.7	15.3	14.0			
Net Profit	£m	-0.029	0.014	-0.16	21.2	14.0	10.8	4.52		
EPS Reported	p	-39.2	6.45	-49.9	401.3	80.1	43.9			
EPS Normalised	p	-94.8	22.4	-49.9	370.1	82.5	47.0	21.8	23.3	
EPS Growth	%					-77.7	-43.1	-53.7	+7.13	
PE Ratio	x						6.76	14.6	13.6	
PEG	x						n/a	2.05	n/a	
Profitability										
Operating Margin	%		105.1	-15.5	10,177	177.2	96.0			+1,757%
ROA	%		1.3	-7.3	61.3	15.0	7.0			
ROCE	%		2.9	-1.6	34.5	13.1	7.8			+9.5%
ROE	%		19.2	-80.7	95.4	22.5	11.6			+13.6%
Cashflow										
Op. Cashflow ps	p	-201.1	-94.0	-33.8	16.9	15.9	37.2			
Capex ps	p	0.000	0.38	0.000	0.000	0.35	0.013			
Free Cashflow ps	p	-201.1	-94.4	-33.8	16.9	15.6	37.1			
Dividends										
Dividend ps	p				4.50	13.0	16.0	16.0	18.0	
Dividend Growth	%				+188.9	+23.1		+12.5		
Dividend Yield	%				5.04	5.04	5.04	5.67		
Dividend Cover	x				89.2	6.16	2.74	1.36	1.29	
Balance Sheet										
Cash etc	£m	0.008	0.15	0.039	5.12	13.3	8.58			+312.9%
Working Capital	£m	-0.13	0.006	-0.14	2.89	12.2	2.86			
Net Fixed Assets	£m	0.000	2.02	2.02	60.1	104.5	175.7			
Net Debt	£m	0.053	1.67	1.78	14.7	23.7	65.4			
Book Value	£m	-0.13	0.27	0.13	44.4	80.0	106.8			
Average Shares	m	0.073	0.22	0.32	5.29	17.5	24.6			+221.1%
Book Value ps	p	-172.2	85.3	38.5	356.7	395.6	414.3			

Health Trend

Piotroski F-Score  4

Bankruptcy Risk

Altman Z-Score  n/a

Earnings Manipulation Risk

N/A

Magic Formula Score

1088 59% C+




Other Ratios

Leverage (ttm)		total	ex intang
Gross Gearing	%	69.3	69.3
Net Gearing	%	61.3	61.3
Cash / Assets	%	4.57	
Liquidity (ttm)			
Curr. Ratio	1.32	Asset Turnover	0.083
Quick Ratio	1.32	Rec's Turnover	4.98
Interest Cov.	7.95	Stock Turnover	n/a

Recent History

Latest interim period (ended 31st Mar '16) vs. prior year		
Sales Growth	27.0 %	
EPS Growth	-43.9 %	
3yr Compound Annual Growth Rate		
Sales Growth	318 %	
EPS Growth	n/a %	
DPS Growth	n/a %	

Graphical History Current Fiscal Year 2017



Broker Forecasts


31st Mar 2017

31st Mar 2018

Broker Consensus Trend

1 Brokers 

Price Target: N/A	Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a	(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate	4.52m	21.8	16.0	-	23.3	18.0
1m Change	-	-	-	-	+0.10	-
3m Change	-	+0.65	+2.00	-	-	-



Profile Summary


Palace Capital plc is a property investment company. The Company invests in commercial real estate in the United Kingdom. The Company's property portfolio includes investment properties located throughout England, predominantly regional investments outside London and consists of a diverse portfolio of commercial buildings. The Company's properties include Hudson House, York; FRASER HOUSE, STAINES, and MIDSUMMER BOULEVARD, MILTON KEYNES. The Company invests in a range of sectors, such as leisure, auto, legal, hotels, retail, health, research and development, and car parking. The Company's subsidiaries include Palace Capital (Leeds) Limited, Palace Capital (Northampton) Limited, Palace Capital (Properties) Limited, Palace Capital (Developments) Limited, Palace Capital (Halifax) Limited and Property Investment Holdings Limited.

Directors: [Stephen Silvester \(FID\) 33](#), [Ronald Sinclair \(MDR\)](#), [Richard Starr \(EDR\) 39](#), [David Kaye \(SEC\)](#), [Stanley Davis \(NEC\)](#), [Anthony Dove \(NED\) 66](#), [Kim Taylor-Smith \(NED\)](#),

No. of Employees: 9

No. of Shareholders: n/a

Last Annual	March 31st, 2016	Sector	Financials
Last Interim	March 31st, 2016	Industry	Real Estate Operations
Incorporated	January 14, 2005	Index	FTSE Aim All Share , FTSE 350 Lower Yield ,
Public Since	October 21, 2013	Exchange	London Stock Exchange (AIM)
Shares in Issue	25,966,629	Eligible for	an ISA? ☒ a SIPP? ☒
Free Float	22.9m (88.3%)		



Address 41 Chalton Street, LONDON, NW1 1JD, United Kingdom
Web <http://www.palacecapitalplc.com/>
Phone +44 20 75542222
Contact David Kaye (Company Secretary)
Auditors BDO LLP


PCAQuote

PCA Share Price Gbp **Day's Change**
317.5p **◆ 0.0 0.0%**

Traded 1:21pm · Minimum 15 min delayed · NMS: 1.000k

Volume	Bid - Ask	Low - High	Spread
5,425	310.0 - 325.0	0.0 - 0.0	472bps
Avg Vol (3m)	Open - Close	12m Range	Beta
12,502	317.5 - 317.5	0.0 - 0.0	0.15

PCA Share Price Performance



Latest PCA News Announcements (delayed)

[More »](#)

7th Jul	Extension of financing facilities
6th Jul	Result of AGM
4th Jul	Grant of awards under LTIP
1st Jul	Disposal of property
22nd Jun	Director Shareholding

Upcoming PCA Events

Recent ↓

Industry Peer Group

	Foxtons Compare vs PCA
	Capital & Regional Compare vs PCA
	Mountview Estates Compare vs PCA
	CLS Holdings Compare vs PCA
	St. Modwen Propert... Compare vs PCA
	BBGI SICAV SA Compare vs PCA
	Market Tech Holdin... Compare vs PCA
	Grainger Compare vs PCA

[Financials](#)

[Real Estate Operations](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2016.